What is Absci?
Absci Corporation operates at the vanguard of the biopharmaceutical industry, utilizing a unique synthesis of data science and advanced biological research. By integrating generative artificial intelligence with high-throughput laboratory experimentation, the firm streamlines the identification and optimization of biologic drug candidates. This data-driven methodology allows for a more precise and efficient discovery process, significantly reducing the time and cost associated with bringing innovative treatments to market. As a key player in the life sciences sector, Absci is redefining how therapeutic molecules are engineered, positioning itself as an essential partner for organizations seeking to modernize their R&D pipelines through digital transformation.
How much funding has Absci raised?
Absci has raised a total of $286.9M across 7 funding rounds:
Series A
$5.1M
Series C
$12M
Multiple Rounds
$80.8M
Other Financing Round
$125M
Other Financing Round
$64M
Series A (2016): $5.1M with participation from Oregon Venture Fund and Phoenix Venture Partners
Series C (2018): $12M led by Oregon Venture Fund, Greenbridge Partners, and Phoenix Venture Partners
Series D (2020): $15.4M supported by Phoenix Venture Partners, Columbia Ventures Corporation, JSR Life Sciences, KBI Biopharma, Washington Research Foundation, and Oregon Venture Fund
Debt (2020): $350K featuring PPP
Series E (2020): $65M backed by Casdin Capital
Other Financing Round (2021): $125M with participation from Redmile Group , LLC and Casdin Capital , LLC
Other Financing Round (2025): $64M, investors not publicly disclosed
Key Investors in Absci
Oregon Venture Fund
Oregon Venture Fund is dedicated to investing in and supporting the next generation of world-class growth companies, focusing on ambitious founding teams with innovative solutions.
Phoenix Venture Partners
PVP is a venture capital firm that specializes in transforming innovative technologies into market-ready products, with a focus on advanced materials and life sciences.
Casdin Capital
Casdin Capital brings a deep understanding and long-term perspective to financing the next generation of life science innovation, particularly in diagnostics and molecular information.
What's next for Absci?
With the recent influx of capital, Absci is well-positioned to expand its technological infrastructure and deepen its research capabilities. The company's strategic roadmap likely involves scaling its AI-driven platform to address more complex disease targets and forging additional partnerships within the pharmaceutical landscape. By maintaining its focus on high-impact therapeutic areas, Absci aims to solidify its market dominance, ensuring that its generative models continue to set the standard for efficiency and innovation in the global drug discovery ecosystem.
See full Absci company page
